AstraZeneca has signed a deal worth up to $247mn with Absci Corporation of the US to design an antibody to fight cancer, the latest tie-up in fast-expanding efforts to use artificial intelligence for drug discovery.
The collaboration aims to harness Absci’s AI technology for large-scale protein analysis to find a viable oncology therapy — a leading focus of Anglo-Swedish drugmaker AstraZeneca.
您已阅读19%（506字），剩余81%（2187字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。